Dark mode is part of the Premium plan.

It is included in the free trial.

Sign inSee Premium
Create a free account
Create a free account

Feeds › 8-K events

8-K events

Major news companies must report to the SEC: results, deals, leadership changes.

About this data
What it is
A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
Who files it
The company, usually within four business days of the event.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.

All of this comes from public filings.

Source and freshness · Information, not investment advice (disclaimer).

8-K items filed per day, last 30 days

05001,0001,500Oct 17 · All items: 0Oct 17 · Earnings results (2.02): 0Oct 17Oct 18 · All items: 0Oct 18 · Earnings results (2.02): 0Oct 19 · All items: 312Oct 19 · Earnings results (2.02): 30Oct 20 · All items: 324Oct 20 · Earnings results (2.02): 67Oct 21 · All items: 381Oct 21 · Earnings results (2.02): 105Oct 21Oct 22 · All items: 460Oct 22 · Earnings results (2.02): 136Oct 23 · All items: 353Oct 23 · Earnings results (2.02): 37Oct 24 · All items: 0Oct 24 · Earnings results (2.02): 0Oct 25 · All items: 0Oct 25 · Earnings results (2.02): 0Oct 25Oct 26 · All items: 388Oct 26 · Earnings results (2.02): 65Oct 27 · All items: 497Oct 27 · Earnings results (2.02): 162Oct 28 · All items: 538Oct 28 · Earnings results (2.02): 228Oct 29 · All items: 677Oct 29 · Earnings results (2.02): 291Oct 29Oct 30 · All items: 355Oct 30 · Earnings results (2.02): 66Oct 31 · All items: 0Oct 31 · Earnings results (2.02): 0Nov 1 · All items: 0Nov 1 · Earnings results (2.02): 0Nov 2 · All items: 526Nov 2 · Earnings results (2.02): 129Nov 2Nov 3 · All items: 583Nov 3 · Earnings results (2.02): 224Nov 4 · All items: 812Nov 4 · Earnings results (2.02): 389Nov 5 · All items: 1,050Nov 5 · Earnings results (2.02): 519Nov 6 · All items: 391Nov 6 · Earnings results (2.02): 90Nov 6Nov 7 · All items: 0Nov 7 · Earnings results (2.02): 0Nov 8 · All items: 0Nov 8 · Earnings results (2.02): 0Nov 9 · All items: 531Nov 9 · Earnings results (2.02): 212Nov 10 · All items: 515Nov 10 · Earnings results (2.02): 169Nov 10Nov 11 · All items: 0Nov 11 · Earnings results (2.02): 0Nov 12 · All items: 730Nov 12 · Earnings results (2.02): 280Nov 13 · All items: 416Nov 13 · Earnings results (2.02): 93Nov 14 · All items: 0Nov 14 · Earnings results (2.02): 0Nov 14Nov 15 · All items: 0Nov 15 · Earnings results (2.02): 0
05001,0001,500Oct 17 · All items: 0Oct 17 · Earnings results (2.02): 0Oct 17Oct 18 · All items: 0Oct 18 · Earnings results (2.02): 0Oct 19 · All items: 312Oct 19 · Earnings results (2.02): 30Oct 20 · All items: 324Oct 20 · Earnings results (2.02): 67Oct 21 · All items: 381Oct 21 · Earnings results (2.02): 105Oct 21Oct 22 · All items: 460Oct 22 · Earnings results (2.02): 136Oct 23 · All items: 353Oct 23 · Earnings results (2.02): 37Oct 24 · All items: 0Oct 24 · Earnings results (2.02): 0Oct 25 · All items: 0Oct 25 · Earnings results (2.02): 0Oct 25Oct 26 · All items: 388Oct 26 · Earnings results (2.02): 65Oct 27 · All items: 497Oct 27 · Earnings results (2.02): 162Oct 28 · All items: 538Oct 28 · Earnings results (2.02): 228Oct 29 · All items: 677Oct 29 · Earnings results (2.02): 291Oct 29Oct 30 · All items: 355Oct 30 · Earnings results (2.02): 66Oct 31 · All items: 0Oct 31 · Earnings results (2.02): 0Nov 1 · All items: 0Nov 1 · Earnings results (2.02): 0Nov 2 · All items: 526Nov 2 · Earnings results (2.02): 129Nov 2Nov 3 · All items: 583Nov 3 · Earnings results (2.02): 224Nov 4 · All items: 812Nov 4 · Earnings results (2.02): 389Nov 5 · All items: 1,050Nov 5 · Earnings results (2.02): 519Nov 6 · All items: 391Nov 6 · Earnings results (2.02): 90Nov 6Nov 7 · All items: 0Nov 7 · Earnings results (2.02): 0Nov 8 · All items: 0Nov 8 · Earnings results (2.02): 0Nov 9 · All items: 531Nov 9 · Earnings results (2.02): 212Nov 10 · All items: 515Nov 10 · Earnings results (2.02): 169Nov 10Nov 11 · All items: 0Nov 11 · Earnings results (2.02): 0Nov 12 · All items: 730Nov 12 · Earnings results (2.02): 280Nov 13 · All items: 416Nov 13 · Earnings results (2.02): 93Nov 14 · All items: 0Nov 14 · Earnings results (2.02): 0Nov 14Nov 15 · All items: 0Nov 15 · Earnings results (2.02): 0

All items Earnings results (2.02)

One filing can report several items. Item 9.01, which only lists attached documents, is not counted.

Latest 8-K filings

Reset

Showing: ticker ALZN

Latest 8-K filings
FiledCompanyItemFormFiling
Nov 10, 2026ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K/A8-K ↗
Nov 10, 2026ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K/A8-K ↗
Nov 10, 2026ALZN
Alzamend Neuro, Inc.
1.01 Entry into a Material Definitive Agreement8-K/A8-K ↗
Sep 29, 2026ALZN
Alzamend Neuro, Inc.
7.01 Regulation FD Disclosure8-K8-K ↗
Aug 3, 2026ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K8-K ↗
Aug 3, 2026ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K8-K ↗
Aug 3, 2026ALZN
Alzamend Neuro, Inc.
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule8-K8-K ↗
Aug 3, 2026ALZN
Alzamend Neuro, Inc.
1.01 Entry into a Material Definitive Agreement8-K8-K ↗
Jul 21, 2026ALZN
Alzamend Neuro, Inc.
8.01 Other Events8-K8-K ↗
Apr 17, 2026ALZN
Alzamend Neuro, Inc.
5.07 Submission of Matters to a Vote of Security Holders8-K8-K ↗
Mar 20, 2026ALZN
Alzamend Neuro, Inc.
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule8-K8-K ↗
Mar 6, 2026ALZN
Alzamend Neuro, Inc.
1.01 Entry into a Material Definitive Agreement8-K8-K ↗
Nov 18, 2025ALZN
Alzamend Neuro, Inc.
8.01 Other Events8-K8-K ↗
Oct 14, 2025ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K8-K ↗
Oct 9, 2025ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K8-K ↗
Sep 25, 2025ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K8-K ↗
Aug 1, 2025ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K8-K ↗
Jul 23, 2025ALZN
Alzamend Neuro, Inc.
2.02 Results of Operations and Financial Condition8-K8-K ↗
Jul 9, 2025ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K8-K ↗
May 8, 2025ALZN
Alzamend Neuro, Inc.
7.01 Regulation FD Disclosure8-K8-K ↗
May 8, 2025ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K8-K ↗
Apr 25, 2025ALZN
Alzamend Neuro, Inc.
5.07 Submission of Matters to a Vote of Security Holders8-K8-K ↗
Mar 3, 2025ALZN
Alzamend Neuro, Inc.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K8-K ↗
Feb 28, 2025ALZN
Alzamend Neuro, Inc.
3.02 Unregistered Sales of Equity Securities8-K8-K ↗
Feb 28, 2025ALZN
Alzamend Neuro, Inc.
1.01 Entry into a Material Definitive Agreement8-K8-K ↗
Dec 12, 2024ALZN
Alzamend Neuro, Inc.
2.02 Results of Operations and Financial Condition8-K8-K ↗

26 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:22 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances